13 results about "Fingolimod" patented technology

The present invention relates to a pharmaceutical composition, quasi-drug composition, or cosmetic composition for the prevention, improvement, or treatment of skin diseases, comprising as an active ingredient a tubulin inhibitor and one or more compounds selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof. The combination therapy of the present invention can be used as an active ingredient that simultaneously exhibits activities such as skin moisturizing, whitening, wrinkle improvement, acne relief, skin barrier strengthening, or keratinocyte differentiation, along with the prevention, treatment, or improvement of skin diseases.

Systems and methods are provided that assess eye movement in multiple sclerosis (MS) patients receiving different drugs (e.g., dimethyl fumarate, fingolimod, clababine, ofarmumab) or treatments that (a) alleviate inflammation that may cause a symptom of multiple sclerosis and prevent nerve injury that may cause a symptom of multiple sclerosis); (b) testing sphingosine-1-phosphate receptor modulators that chelate lymphocytes in the lymphocyte nodes, preventing them from causing an autoimmune response); (c) checking for immunosuppressants acting on the lymphocyte pathway); and (d) analyzing the effect of the monoclonal antibody in inhibiting activation of lymphocyte B.

Provided are a pharmaceutical salt of Fingolimod, preparation method, pharmaceutical composition and use thereof. The pharmaceutical salt of Fingolimod is a salt formed from a Fingolimod free base and an organic acid having at least six carbon atoms. The pharmaceutical salt of Fingolimod has better solubility and stability, and a good market prospect.

The present invention relates to the use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, belonging to the field of pharmaceutical technology. The use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, the chemical structural formula of the fingolimod is as follows. The present invention adopts the administration method of oral and nasal inhalation, uses fingolimod to treat ischemic stroke, enhances the aggregation of the drug in the lungs, inhibits the migration of pulmonary immune cells to the brain, thereby reducing the inflammation at the stroke site in the brain parenchyma, improving the damage to the nervous system at the stroke site, and promoting the recovery of damaged nerve function. Moreover, the oral and nasal inhalation administration method avoids the side effects such as cardiac conduction block and bradycardia that may be caused when fingolimod is taken orally, and provides a new type of safe and effective administration route for patients with cerebral infarction, especially those with heart disease.

The present disclosure relates to a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition comprising: a tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof as active ingredients for the prevention, alleviation, or treatment of skin diseases. The combination therapy of the present invention can be utilized as an active ingredient simultaneously exhibiting activities such as skin moisturizing, whitening, wrinkle alleviation, acne alleviation, skin barrier strengthening, or skin keratinocyte differentiation, in addition to preventing, treating, or alleviating skin diseases.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and contin- ued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

A preparation method of a cholesterol modified fingolimod prodrug for targeted inhibition of neuroinflammation comprises the following steps: preparing reactive oxygen species (ROS) responsive cholesterol and a fingolimod-BOC intermediate, and then dissolving the ROS responsive cholesterol in absolute methanol to obtain an ROS responsive cholesterol methanol solution; dropwise adding the methanol solution of the fingolimod-BOC intermediate into the ROS response cholesterol methanol solution, magnetically stirring in the whole process, stirring and reacting at normal temperature for 1-3 hours after dropwise adding, and removing the solvent to obtain a target product. The fingolimod molecular design is positively innovated for neuroinflammation inhibition. By adopting the design of the fingolimod prodrug, the blood-brain barrier penetrating power of the drug is improved, and meanwhile, prodrug molecules can be selectively activated at neuroinflammation parts, so that microglial cells are promoted to be transformed from an M1 pro-inflammatory type to an M2 anti-inflammatory type, nerve cells are protected, nerve injury at the inflammation parts is repaired, and the toxic and side effects of fingolimod are remarkably reduced.

The invention relates to the technical field of biological medicine, and discloses fingolimod-loaded nanoparticles and a preparation method thereof, and the preparation method comprises the following steps: synthesizing CeO2 nanoparticles through a high-temperature organic solution phase method; the preparation method comprises the following steps: adding CeO2 nanoparticles into polyethylene glycol to obtain PEG-CeO2 nanoparticles, and modifying the surfaces of the CeO2 nanoparticles by the polyethylene glycol to form a coating layer; the fingolimod and the PEG-CeO2 nano particles are mixed, and the fingolimod is attached to the surface of the coating layer, so that CeO2-FTY 720 nano particles are prepared; the invention also discloses application of the medicine in treating cerebral hemorrhage. According to the present invention, the dual characteristics of CeO2 nanoparticles and fingolimod are inherited, the use of the single component is reduced, the characteristics such as antioxidant activity and the like are superior to the characteristics of the single component and the simple superposition of the components, and the functional synergistic interaction is achieved.

The invention discloses fingolimod-modified selenium nanoparticles as well as a preparation method and application thereof, and fingolimod containing amino and hydroxyl is added in the process of preparing the selenium nanoparticles by reducing selenium-containing salt with a reducing agent, so that the fingolimod-modified selenium nanoparticles are obtained. The fingolimod-modified selenium nanoparticles prepared by the invention can be used as a nano-scale drug to carry out intracerebral anti-oxidation and anti-inflammatory treatment in vivo level, alleviate the tau protein phosphorylation process in neurons, inhibit neuronal death, regulate microglial cell polarization in the brain and play a neuroinflammation protection function, and can be used for preparing a drug for treating neuroinflammation. Neuroprotection and selenium nanoparticles are combined, and the treatment effect of the Alzheimer's disease is enhanced through a synergistic mechanism, so that a more effective strategy is possibly provided for treatment of the Alzheimer's disease.

The present invention relates to the treatment of disorders using sphingosine-1-phosphate receptor modulators. Specifically, the present invention relates to the treatment of neurological disorders such as multiple sclerosis using sphingosine-1-phosphate receptor modulators such as fingolimod. Also disclosed are compositions for administration of the sphingosine-1-phosphate receptor modulator to a subject; methods for manufacturing such compositions; and methods of delivering the sphingosine- 1-phosphate receptor modulator to a subject.

The application discloses application of fingolimod in preparation of prevention, improvement, treatment or adjuvant treatment of hepatolenticular degeneration, and relates to the field of medicine. Through in-vivo experiment research, it is found that fingolimod (FTY720) can improve the liver phenotype of a hepatolenticular degeneration mouse by blocking sphingosine-1-phosphate (S1P) signal transmission, and the drug use scheme of FTY720 in improving the liver symptoms of the mouse can be used for treating liver-type hepatolenticular degeneration; and the treatment potential of FTY720 on hepatolenticular degeneration is confirmed, thereby providing a new selection for treatment of hepatolenticular degeneration.

This invention belongs to the field of biomedical technology and discloses a methylene blue-fingolimod prodrug based on hypochlorous acid activation, its preparation method, and its application. Fingolimod and methylene blue, which has hypochlorous acid scavenging and neuroprotective functions, are bonded together via a hypochlorous acid-sensitive thioether bridge. This design cleverly utilizes the abnormally high concentration of hypochlorous acid within the lesion as "molecular scissors," achieving precise activation of the prodrug at the target site and synergistic release of both drugs. This not only endows fingolimod with targeted noise reduction and enhanced efficacy but also simultaneously implements a combined attack of "detoxification" and "anti-inflammation," thereby more thoroughly breaking the damage cascade and providing a novel synergistic solution for stroke treatment.